Skip to main content
Premium Trial:

Request an Annual Quote

CardioDx Withdraws IPO

NEW YORK (GenomeWeb) – Calling current market conditions unattractive, cardiovascular disease molecular diagnostics firm CardioDx is withdrawing its planned initial public offering.

The company filed a request with the US Securities and Exchange Commission on Tuesday to withdraw its IPO, saying, "The terms currently obtainable in the public marketplace are not sufficiently attractive to the [company] to warrant proceeding with the public offering."

The Palo Alto, Calif.-based firm filed a registration statement with the SEC in October 2013 to go public with intentions of raising up to $86.3 million. That amount was increased to $92 million a month later.

Last week, CardioDx said that it raised $35 million in a round of private financing. The company develops molecular diagnostics with an initial focus on coronary artery diseases, arrhythmia, and heart failure. Its flagship product is Corus CAD, a gene expression-based test for assessing non-diabetic patients who display symptoms suggestive of obstructive CAD.

 

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.